Results 141 to 150 of about 33,038 (222)

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F.   +27 more
europepmc   +1 more source

Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review). [PDF]

Int J Oncol
Wang Y, Xie Y, Zhao Q.
europepmc   +1 more source

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. [PDF]

Adv Sci (Weinh)
Zhang C, Cheong TL, Narwade N, Dong D, Deng M, Miao Z, Ding Z, Li W, Lei KMK, Wei GH, Poon TCW, Deng CX, Cheung E.   +12 more
europepmc   +1 more source

Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer. [PDF]

Discov Oncol
Lilleby W, Geinitz H, Denmeade S.
europepmc   +1 more source

Immune-inflammation index as prognostic markers in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Qin Z, Liu R, Jing S, Guo C, Li W.
europepmc   +1 more source

Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation. [PDF]

Front Oncol
Xing Y, Xiang L, Jia Y, Yang Y.
europepmc   +1 more source

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. [PDF]

Cancer Res
Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E.   +31 more
europepmc   +1 more source

The pterocarpan (+)-PTC modulates cytoskeletal proteins and induces apoptosis in metastatic castration-resistant prostate cancer: a proteomic perspective. [PDF]

Front Pharmacol
de Brito Vieira Neto J, Moraes de Farias K, Alves Sales SL, Melo VB, Nascimento Macêdo SM, Koscky Paier CR, Bezerra MJ, Moura AA, Carvalho HF, Domingos de Sousa F, Aquino A, de Oliveira Monteiro AC, Martins-de-Souza D, Banwell MG, Miranda Furtado CL, Pessoa C.   +15 more
europepmc   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide. [PDF]

Cancer Med
Brown JT, Nazha B, Ferreira AC, Armeson K, Hill EG, Ogretmen B, Mehrotra S, Brisendine A, Magrath G, Plasse TF, Gourdin TS, Kucuk O, Lilly M.   +12 more
europepmc   +1 more source